There is potential for further improvement of anti-CD19 CAR T-cell therapy efficacy through various approaches, such as administering a second infusion or combination of CAR T-cells with other anti-CLL agents such as BTKi, BCL-2 or PI3 kinase inhibitors.38,39. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.